Trial Profile
A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combination tablet of emtricitabine and tenofovir DF [tenofovir disproxil fumarate] versus twice daily co-formulated zidovudine and lamivudine (Combivir) or zidovudine and lamivudine, in virologically suppressed, HIV infected patients taking efavirenz
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Efavirenz; Lamivudine; Lamivudine/zidovudine; Zidovudine
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms SWEET
- Sponsors Gilead Sciences
- 26 Jun 2019 Status changed from active, no longer recruiting to completed.
- 15 Aug 2009 Tolerability data were published in the Journal of Acquired Immune Deficiency Syndrome.
- 25 Jul 2007 Interim results were reported at IAS.